Neuvivo, Inc.

About Neuvivo

Neuvivo develops experimental medicines for people with diseases that damage nerve cells and muscle control. Its lead candidate, NP001, targets amyotrophic lateral sclerosis (ALS). The immune therapy is delivered into the bloodstream and is designed to reduce nerve-damaging inflammation. NP001 remains investigational and has not received FDA approval. Neuvivo's platform includes a patented NP001 formulation and manufacturing process.

The Palo Alto company is in late-stage clinical development. NP001 has FDA Orphan Drug and Fast Track designations. Two Phase 2 studies generated data from about 300 patients. Michael McGrath became chief executive officer in November 2026.

Funding Rounds (SEC Form D)

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

What the SEC Filings Show

• Virit Vichitvadakan of PrimeStreet Capital, which led the Venture financing round, first appears as a director on the Form D that Neuvivo filed on November 13, 2026. [12][6][11]

Who Invested in Neuvivo

Scroll table to see all columns →

Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.

Why Investors Backed Neuvivo

Available ALS medicines do not preserve breathing or extend life by more than two to three months. PrimeStreet Capital saw Neuvivo's therapeutic work as a chance to improve many lives and paired its funding with strategic support. [5][6]

Origin and Team

Neuvivo launched in December 2021 with co-founders Ari Azhir and Michael McGrath. Azhir had experience at Roche, Intermune and BD. His background also included Neuraltus. McGrath had experience at Stanford, UCSF and Neuraltus. [10]

Product and Technology

NP001 is delivered by infusion into the bloodstream. Immune cells convert this small-molecule prodrug into taurine chloramine, which regulates inflammatory activity. Early patents for the technology are licensed from UCSF. [2][9]

In a post-hoc Phase 2B analysis, a patient subset saw 36% slower functional decline and 51% slower respiratory decline over six months. The subset was ages 40 to 65, with CRP above 1.13 mg/L and symptoms starting within three years. Among treated patients, 34% did not progress, versus 11% on placebo. The study found NP001 safe and well tolerated. [8]

Use of Funds

• The 2023 financing was designated for continued NP001 development as an ALS treatment. [6]
• The 2022 financing was intended to continue development of NP001 for ALS. [7]

Milestones

Scroll table to see all columns →

We wrote this summary from public statements by Neuvivo and its investors. It is not investment advice.

Leadership Team

Executive officers and directors listed on Neuvivo's Form D filed Nov 13, 2026.

Largest Form D Raises Filed the Same Day

Private companies with new Form D filings accepted by the SEC on Nov 13, 2026.

Sources

1. CompanyNeuvivo home page · linked above ↑
2. CompanyAbout NP001
3. CompanyNeuvivo news index
4. CompanyFDA pathway and John Curnutte announcement
5. CompanyMark Henderson appointment
6. Company2023 financing announcement
7. Company2022 additional financing announcement
8. CompanyPhase 2B publication announcement
9. CompanyType C meeting request announcement
10. CompanyCorporate launch announcement
11. PressPR Newswire 2023 financing release
12. SECNeuvivo Form D, filed 2026-11-13 · linked above ↑
13. SECNeuvivo, Inc. filing history